Lonez C, Bolsee J, Huberty F, Nguyen T, Jacques-Hespel C, Anguille S
Int J Mol Sci. 2025; 26(4).
PMID: 40004122
PMC: 11855736.
DOI: 10.3390/ijms26041658.
Zhu E, Yu J, Li Y, Ma F, Wang Y, Liu Y
Nat Nanotechnol. 2024; 19(12):1914-1922.
PMID: 39313679
DOI: 10.1038/s41565-024-01781-4.
Volpe A, Lyashchenko S, Ponomarev V
Mol Imaging Biol. 2024; 26(4):555-568.
PMID: 38958882
PMC: 11281953.
DOI: 10.1007/s11307-024-01923-z.
Renner A, Stahringer A, Ruppel K, Fricke S, Koehl U, Schmiedel D
Gene Ther. 2024; 31(7-8):378-390.
PMID: 38684788
PMC: 11257948.
DOI: 10.1038/s41434-024-00454-0.
Pramono D, Takeuchi D, Katsuki M, AbuEed L, Abdillah D, Kimura T
J Virol. 2024; 98(4):e0177123.
PMID: 38440982
PMC: 11019853.
DOI: 10.1128/jvi.01771-23.
Meeting FDA Guidance recommendations for replication-competent virus and insertional oncogenesis testing.
Cornetta K, Lin T, Pellin D, Kohn D
Mol Ther Methods Clin Dev. 2023; 28:28-39.
PMID: 36588821
PMC: 9791246.
DOI: 10.1016/j.omtm.2022.11.009.
Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials.
Cornetta K, Yao J, House K, Duffy L, Adusumilli P, Beyer R
Mol Ther. 2022; 31(3):801-809.
PMID: 36518078
PMC: 10014217.
DOI: 10.1016/j.ymthe.2022.12.006.
Inadvertent Transfer of Murine VL30 Retrotransposons to CAR-T Cells.
Lee S, Hao Y, Gui T, Dotti G, Savoldo B, Zou F
Adv Cell Gene Ther. 2022; 2022.
PMID: 36081760
PMC: 9450689.
DOI: 10.1155/2022/6435077.
Isolation of TCR genes with tumor-killing activity from tumor-infiltrating and circulating lymphocytes in a tumor rejection cynomolgus macaque model.
Terada K, Kondo K, Ishigaki H, Nagashima A, Satooka H, Nagano S
Mol Ther Oncolytics. 2022; 24:77-86.
PMID: 35024435
PMC: 8717465.
DOI: 10.1016/j.omto.2021.12.003.
Efficient Pseudotyping of Different Retroviral Vectors Using a Novel, Codon-Optimized Gene for Chimeric GALV Envelope.
Mirow M, Schwarze L, Fehse B, Riecken K
Viruses. 2021; 13(8).
PMID: 34452336
PMC: 8402753.
DOI: 10.3390/v13081471.
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells.
Moore T, Scurti G, DeJong M, Wang S, Dalheim A, Wagner C
Mol Ther Oncolytics. 2021; 20:352-363.
PMID: 33614916
PMC: 7878989.
DOI: 10.1016/j.omto.2021.01.014.
Human T Cells Expressing a CD19 CAR-T Receptor Provide Insights into Mechanisms of Human CD19-Positive β Cell Destruction.
Ma H, Jeppesen J, Jaenisch R
Cell Rep Med. 2020; 1(6):100097.
PMID: 33205073
PMC: 7659530.
DOI: 10.1016/j.xcrm.2020.100097.
Demonstration of anti-tumour bystander killing with prodrug-preloaded suicide gene-engineered tumour cells: a potential improvement for cancer therapeutics.
Zweiri J, Christmas S
Cancer Cell Int. 2020; 20:26.
PMID: 32002015
PMC: 6986055.
DOI: 10.1186/s12935-020-1115-4.
Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience.
Cornetta K, Duffy L, Feldman S, Mackall C, Davila M, Curran K
Mol Ther Methods Clin Dev. 2018; 10:371-378.
PMID: 30211249
PMC: 6134358.
DOI: 10.1016/j.omtm.2018.08.006.
Continuous production process of retroviral vector for adoptive T- cell therapy.
Inwood S, Xu H, Black M, Betenbaugh M, Feldman S, Shiloach J
Biochem Eng J. 2018; 132:145-151.
PMID: 29977134
PMC: 6028049.
DOI: 10.1016/j.bej.2018.01.010.
The impact of γ-irradiation on the induction of bystander killing by genetically engineered ovarian tumor cells: implications for clinical use.
Zweiri J, Christmas S
Cancer Cell Int. 2017; 17:96.
PMID: 29089859
PMC: 5655875.
DOI: 10.1186/s12935-017-0465-z.
Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.
Cornetta K, Duffy L, Turtle C, Jensen M, Forman S, Binder-Scholl G
Mol Ther. 2017; 26(1):280-288.
PMID: 28970045
PMC: 5762981.
DOI: 10.1016/j.ymthe.2017.09.008.
Interactions between HIV-1 Gag and Viral RNA Genome Enhance Virion Assembly.
Dilley K, Nikolaitchik O, Galli A, Burdick R, Levine L, Li K
J Virol. 2017; 91(16).
PMID: 28539452
PMC: 5533913.
DOI: 10.1128/JVI.02319-16.
Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.
Riviere I, Sadelain M
Mol Ther. 2017; 25(5):1117-1124.
PMID: 28456379
PMC: 5417838.
DOI: 10.1016/j.ymthe.2017.03.034.
Clinical manufacturing of CAR T cells: foundation of a promising therapy.
Wang X, Riviere I
Mol Ther Oncolytics. 2016; 3:16015.
PMID: 27347557
PMC: 4909095.
DOI: 10.1038/mto.2016.15.